mProX™ Human SLC6A3 Stable Cell Line

Product Information

Target Protein

SLC6A3

Target Family

SLC Transporter

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Transporter Cell Lines

Target Research Area

CNS Research; Pain and Addiction Research

Related Diseases

Parkinsonism-Dystonia; Tobacco Addiction

Gene ID

6531

UniProt ID

Q01959

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The dopamine transporter, or DAT, is a protein that is made using instructions provided by the SLC6A3 gene. This protein carries a chemical known as dopamine into the cell by embedding itself in the membrane of specific brain nerve cells. Dopamine is released into the area between neurons in order to transfer messages, where it binds to receptors on the surface of nearby neurons. The dopamine transporter recycles dopamine in neurons from the synaptic cleft. How much and how long dopamine is present in the synaptic cleft depends on the transporter's activity. The transporter becomes a key modulator of dopamine signaling in the brain as a result of this activity. The customized SLC6A3 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Donna

The SLC6A3 cell line is easy to handle and has shown consistent performance in various experimental setups. May 06 2020

chat Verified Customer

chat Nancy

I recently had the opportunity to try the human SLC6A3 cell line from Creative Biolabs. The provided instructions were clear and easy to follow. Mar 27 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 To ascertain the protein expression in eight comparable normal (N) and clear cell renal cell carcinoma (T) tissues, Western blot assays were conducted.

Western Blot studies were used to assess the expression of FXYD4, SLC6A3, SLC12A1, NPTX2, NDUF4AL2, and KNG1 in homogenized renal tissue. Tumor tissues showed a substantial increase in NPTX2 expression. The expression of FXYD4, KNG1, and SLC12A1 was downregulated in ccRCC tissues. The levels of SLC6A3 and NDUF4AL2 in tumors were lower than in normal renal tissues, which is in contrast to the mRNA expression.

Ref: Schrödter, Sarah, et al. "Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma." Molecular cancer 15.1 (2016): 1-10.

Pubmed: 26831905

DOI: 10.1186/s12943-016-0495-5

Research Highlights

The human dopamine transporter gene SLC6A3 has been repeatedly linked to a number of neuropsychiatric conditions, although the exact cause of these illnesses is still unknown.
Reith, Maarten EA, et al. "The dopamine transporter gene SLC6A3: multidisease risks." Molecular psychiatry 27.2 (2022): 1031-1046.
Pubmed: 34650206 DOI: 10.1038/s41380-021-01341-5

The novel biomarker SLC6A3, which is highly specific for ccRCC, is the dopamine transporter. We further hypothesise that the protein may be used therapeutically or diagnostically to detect or treat ccRCC.
Hansson, Jennifer, et al. "Overexpression of functional SLC6A3 in clear cell renal cell carcinoma." Clinical Cancer Research 23.8 (2017): 2105-2115.
Pubmed: 27663598 DOI: 10.1158/1078-0432.CCR-16-0496